Inventor · disambiguated record
Jayakanth Kankanala
Also filed as: KANKANALA JAYAKANTH
17 granted patents·24 pending applications·27 citations·filing 2018–2024
90Inventor score
Top patents by PatentIndex Score
41 records- 0194US11834458B2Anti-cancer nuclear hormone receptor-targeting compoundsNUVATION BIO INC·Filed 2022·Granted Dec 5, 2023·2 cites·34 claims
- 0293US12006314B2Anti-cancer nuclear hormone receptor-targeting compoundsNUVATION BIO INC·Filed 2022·Granted Jun 11, 2024·2 cites·17 claims
- 0392US11584756B2Heterocyclic compounds as BET inhibitorsNUVATION BIO INC·Filed 2020·Granted Feb 21, 2023·3 cites·31 claims
- 0490US11952349B2Anti-cancer nuclear hormone receptor-targeting compoundsNUVATION BIO INC·Filed 2020·Granted Apr 9, 2024·2 cites·10 claims
- 0590US11826430B2Anti-cancer nuclear hormone receptor-targeting compoundsNUVATION BIO INC·Filed 2020·Granted Nov 28, 2023·2 cites·8 claims
- 0690US11292782B2Diarylhydantoin compounds and methods of use thereofNUVATION BIO INC·Filed 2019·Granted Apr 5, 2022·6 cites·39 claims
- 0790US11034669B2Pyrrole and pyrazole compounds and methods of use thereofNUVATION BIO INC·Filed 2019·Granted Jun 15, 2021·6 cites·16 claims
- 0881US10807994B2Heterocyclic compounds and uses thereofNUVATION BIO INC·Filed 2018·Granted Oct 20, 2020·3 cites·59 claims
- 0980US12208141B2Anti-cancer nuclear hormone receptor-targeting compoundsNUVATION BIO INC·Filed 2023·Granted Jan 28, 2025·0 cites·19 claims
- 1078US2025276978A1Heterocyclic compounds as bet inhibitorsNUVATION BIO INC·Filed 2024·Application pending·0 cites
- 1176US11174252B2Heterocyclic compounds as kinase inhibitorsNUVATION BIO INC·Filed 2019·Granted Nov 16, 2021·1 cites·106 claims
- 1274US2024352027A1Anti-cancer nuclear hormone receptor-targeting compoundsNUVATION BIO INC·Filed 2023·Application pending·0 cites
- 1368US12398121B2Anti-cancer nuclear hormone receptor-targeting compoundsNUVATION BIO INC·Filed 2022·Granted Aug 26, 2025·0 cites·12 claims
- 1465US2022213122A1Substituted 1,6-dihydropyridinones and 1,2-dihydroisoquinolinones as bet inhibitorsNUVATION BIO INC·Filed 2021·Application pending·0 cites
- 1564US2023118115A1SUBSTITUTED PYRAZOLO[3,4-d]PYRIMIDINES AS WEE1 INHIBITORSNUVATION BIO INC·Filed 2022·Application pending·0 cites
- 1663US2023109104A1Heterocyclic compounds and uses thereofNUVATION BIO INC·Filed 2022·Application pending·0 cites
- 1762US11192900B2Substituted 1,6-dihydropyridinones and 1,2-dihydroisoquinolinones as bet inhibitorsNUVATION BIO INC·Filed 2019·Granted Dec 7, 2021·0 cites·25 claims
- 1862US2022298142A1Heterocyclic compounds as adenosine antagonistsNUVATION BIO INC·Filed 2022·Application pending·0 cites
- 1962US2022169648A11,8-naphthyridinone compounds and uses thereofNUVATION BIO INC·Filed 2022·Application pending·0 cites
- 2061US2019375732A1Anti-cancer nuclear hormone receptor-targeting compoundsHUNG DAVID·Filed 2019·Application pending·0 cites
- 2160US11306071B2Heterocyclic compounds as adenosine antagonistsNUVATION BIO INC·Filed 2020·Granted Apr 19, 2022·0 cites·20 claims
- 2260US2023062022A1Heterocyclic compounds as kinase inhibitorsNUVATION BIO INC·Filed 2021·Application pending·0 cites
- 2360US2024343710A1Heterocyclic compounds and methods of use thereof1CBIO INC·Filed 2024·Application pending·0 cites
- 2458US2024132522A1Heterocyclic compounds and methods of use thereof1CBIO INC·Filed 2023·Application pending·0 cites
- 2558US2024132449A1Heterocyclic compounds and methods of use thereof1CBIO INC·Filed 2023·Application pending·0 cites
- 2656US11332473B2Substituted pyrazolo[3,4-d]pyrimidines as Wee1 inhibitorsNUVATION BIO INC·Filed 2020·Granted May 17, 2022·0 cites·60 claims
- 2756US2023174545A1Heterocyclic compounds as bet inhibitorsNUVATION BIO INC·Filed 2021·Application pending·0 cites
- 2855US2023023009A1Heterocyclic compounds and methods of use thereofSPARCBIO LLC·Filed 2021·Application pending·0 cites
- 2955US2023026856A1Heterocyclic compounds and methods of use thereofSPARCBIO LLC·Filed 2021·Application pending·0 cites
- 3054US11254670B21,8-naphthyridinone compounds and uses thereofNUVATION BIO INC·Filed 2020·Granted Feb 22, 2022·0 cites·37 claims
- 3153US11299493B2Heterocyclic compounds and uses thereofNUVATION BIO INC·Filed 2018·Granted Apr 12, 2022·0 cites·34 claims
- 3250US2022162229A1Heterocyclic compounds and uses thereofNUVATION BIO INC·Filed 2020·Application pending·0 cites
- 3349US2022347187A1Heterocyclic compounds as kinase inhibitorsNUVATION BIO INC·Filed 2020·Application pending·0 cites
- 3449US2022273659A1Heterocyclic compounds as kinase inhibitorsNUVATION BIO INC·Filed 2020·Application pending·0 cites
- 3548US2022281859A1Heterocyclic compounds as kinase inhibitorsNUVATION BIO INC·Filed 2020·Application pending·0 cites
- 3647US10617706B2Compounds for cancer chemotherapeutic sensitizationUNIV MINNESOTA·Filed 2019·Granted Apr 14, 2020·0 cites·17 claims
- 3747US2022220115A1Heterocyclic compounds and uses thereofNUVATION BIO INC·Filed 2020·Application pending·0 cites
- 3846US2022168313A1Heterocyclic compounds and uses thereofNUVATION BIO INC·Filed 2020·Application pending·0 cites
- 3945US2023066315A1Compounds and uses thereofNUVATION BIO INC·Filed 2020·Application pending·0 cites
- 4044US2022169646A1Heterocyclic compounds and uses thereofNUVATION BIO INC·Filed 2020·Application pending·0 cites
- 4143US2022119367A1Heterocyclic compounds as adenosine antagonistsNUVATION BIO INC·Filed 2020·Application pending·0 cites
Join the waitlist — get patent alerts
Get an alert when Jayakanth Kankanala files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →